These treatments are effective--there's no doubt about that. But the glass is only half full.
"Jeffrey Alan Lieberman" (born 1948) is an American psychiatrist who specializes in schizophrenia and related Psychosis/psychoses and their associated neuroscience (biology) and drugs. He was principal investigator for CATIE, the largest and longest independent study ever funded by the United States National Institute of Mental Health to examine existing therapies for schizophrenia. He was past president of the American Psychiatric Association from May 2013 to May 2014.
Lieberman is the Lawrence E. Kolb Professor and chairman of psychiatry at the Columbia University College of Physicians and Surgeons and director of the New York State Psychiatric Institute. He also holds the Lieber Chair and directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia and serves as the psychiatrist in chief of NewYork-Presbyterian Hospital-Columbia University Medical Center.
More Jeffrey Lieberman on Wikipedia.The study demonstrated that these medicines are effective, but that doctors and patients are looking for more. The medicines didn't completely alleviate symptoms or enable the majority of the patients to experience a complete recovery.
What works for one person may not work for another.
The message is the glass is half full, ... The drugs work but they are not satisfactory to many patients, and three-quarters of the people in our study voted with their feet and discontinued the drugs.
Probably the biggest surprise of all was that the older medication produced about as good an effect as the newer medications, three of them anyway, and did not produce neurological side effects at greater rates than any of the other drugs.
When it comes to the treatment of patients with chronic schizophrenia, the glass is only half-full.
The differences observed are not in and of themselves outside the range of variation seen in the normal population.
Copyright © 2024 Electric Goat Media. All Rights Reserved.